{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:43:29Z","timestamp":1793105009001,"version":"4.5.0"},"reference-count":26,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2023,6,18]],"date-time":"2023-06-18T00:00:00Z","timestamp":1687046400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Neurogastroenterology Motil"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Patients with chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS\u2010C) often experience severe symptoms. The current aim was to evaluate plecanatide in adults with CIC or IBS\u2010C with severe constipation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data were analyzed post hoc from randomized, placebo\u2010controlled trials (CIC [<jats:italic>n\u2009=<\/jats:italic>\u20092], IBS\u2010C [<jats:italic>n\u2009=<\/jats:italic>\u20092]) of plecanatide 3\u2009mg, 6\u2009mg, or placebo administered for 12\u2009weeks. Severe constipation was defined as no complete spontaneous bowel movements (CSBMs) and an average straining score\u2009\u22653.0 (CIC; 5\u2010point scale) or \u22658.0 (IBS\u2010C; 11\u2010point scale) during a 2\u2010week screening. Primary efficacy endpoints were durable overall CSBM responders (CIC: \u22653 CSBMs\/week, plus increase from baseline of \u22651 CSBM\/week, for \u22659 of 12\u2009weeks, including \u22653 of the last 4\u2009weeks) and overall responders (IBS\u2010C: \u226530% reduction from baseline in abdominal pain and\u2009\u22651 CSBM\/week increase for \u22656 of 12\u2009weeks).<\/jats:p><\/jats:sec><jats:sec><jats:title>Key Results<\/jats:title><jats:p>Severe constipation was observed in 24.5% (646\/2639) and 24.2% (527\/2176) of CIC and IBS\u2010C populations, respectively. The CIC durable overall CSBM response rate (plecanatide 3\u2009mg, 20.9%; plecanatide 6\u2009mg, 20.2%; placebo, 11.3%) and IBS\u2010C overall response rate (plecanatide 3\u2009mg, 33.0%; plecanatide 6\u2009mg, 31.0%; placebo, 19.0%) were significantly greater with plecanatide versus placebo (<jats:italic>p<\/jats:italic>\u2009\u2264\u20090.01 for all). Median time to first CSBM in CIC and IBS\u2010C populations were significantly shorter with plecanatide 3\u2009mg versus placebo (<jats:italic>p<\/jats:italic>\u2009=\u20090.01 for both).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Inferences<\/jats:title><jats:p>Plecanatide was effective in the treatment of severe constipation in adults with CIC or IBS\u2010C.<\/jats:p><\/jats:sec>","DOI":"10.1111\/nmo.14632","type":"journal-article","created":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T06:03:08Z","timestamp":1687154588000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: Post hoc analyses of placebo\u2010controlled trials in adults with severe constipation"],"prefix":"10.1111","volume":"35","author":[{"given":"Brooks D.","family":"Cash","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition University of Texas Health Science Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5843-1220","authenticated-orcid":false,"given":"Amol","family":"Sharma","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology &amp; Hepatology, Medical College of Georgia Augusta University  Augusta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Walker","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology &amp; Hepatology, Medical College of Georgia Augusta University  Augusta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam P.","family":"Laitman","sequence":"additional","affiliation":[{"name":"Salix Pharmaceuticals  Bridgewater New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6800-2967","authenticated-orcid":false,"given":"Lin","family":"Chang","sequence":"additional","affiliation":[{"name":"Vatche and Tamar Manoukian Division of Digestive Diseases David Geffen School of Medicine at the University of California  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,6,18]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.5056\/jnm16214"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001036"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.04.014"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.12.021"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.164"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2014.187"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.02.031"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16369"},{"issue":"5","key":"e_1_2_10_10_1","first-page":"3","article-title":"Understanding and managing IBS and CIC in the primary care setting","volume":"14","author":"Cash BD","year":"2018","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.03238.x"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.08.016"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12830"},{"key":"e_1_2_10_14_1","first-page":"385","article-title":"Psychometric validation of patient\u2010reported outcome measures assessing chronic constipation","volume":"7","author":"Nelson LM","year":"2014","journal-title":"Clin Exp Gastroenterol"},{"key":"e_1_2_10_15_1","unstructured":"Trulance tablets for oral use.Salix Pharmaceuticals.2021."},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEG.S145668"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.611"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X17734697"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41395-018-0026-7"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365529709011203"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.78"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00404.x"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.16.1773"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2008.01997.x"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001306"},{"key":"e_1_2_10_26_1","doi-asserted-by":"crossref","first-page":"S227","DOI":"10.14309\/01.ajg.0000774508.70937.85","article-title":"Plecanatide provided clinically meaningful improvements in health\u2010related quality of life in patients with chronic idiopathic constipation and irritable bowel syndrome with constipation: a post\u2010hoc analysis [abstract S509]","volume":"116","author":"Brenner DM","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.201"}],"container-title":["Neurogastroenterology &amp; Motility"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/nmo.14632","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T05:04:02Z","timestamp":1691989442000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/nmo.14632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,18]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1111\/nmo.14632"],"URL":"https:\/\/doi.org\/10.1111\/nmo.14632","archive":["Portico"],"relation":{},"ISSN":["1350-1925","1365-2982"],"issn-type":[{"value":"1350-1925","type":"print"},{"value":"1365-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,18]]},"assertion":[{"value":"2023-01-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e14632"}}